Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Part of paid clinical trials in Loma Linda, California.

Sponsor
Alexion Pharmaceuticals, Inc.
Study ID
NCT07157787
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Primary Membranous Nephropathy

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • ALXN1920 — DRUG
    Participants will receive ALXN1920 SC infusion.
  • Placebo — DRUG
    Participants will receive Placebo SC infusion.

Study Details

The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).

Key Dates

Start date
Sep 19, 2025
Status verified
Apr 2026
Primary completion
Jul 2, 2027
Completion
Jul 9, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ALXN1920
    Participants will receive ALXN1920 subcutaneous (SC) and background treatment of ACE/ARB and Rituximab.
  • Experimental: Placebo
    Participants will receive placebo subcutaneous (SC) and background treatment of ACE/ARB and Rituximab.

Primary Outcome Measure

Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26 [ Time Frame: Baseline, Week 26 ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Research SiteLoma LindaCalifornia92354-
Research SiteSan DiegoCalifornia92123-
Research SiteMinneapolisMinnesota55435-
Research SiteRochesterMinnesota55905-
Research SiteHoustonTexas77030-

Find similar trials in Loma Linda, CA

By research site
Research Site· Loma Linda, CAResearch Site· San Diego, CAResearch Site· Minneapolis, MNResearch Site· Rochester, MNResearch Site· Houston, TX

Related Studies